Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 16, 2023; 11(5): 1115-1121
Published online Feb 16, 2023. doi: 10.12998/wjcc.v11.i5.1115
Published online Feb 16, 2023. doi: 10.12998/wjcc.v11.i5.1115
Envafolimab combined with chemotherapy in the treatment of combined small cell lung cancer: A case report
Mei-Hong Liu, Yan-Xia Li, Zhuo Liu, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning Province, China
Author contributions: Liu MH and Liu Z reviewed the literature and contributed to the manuscript collection and interpretation of the clinical data and material; Li YX was responsible for the revision of the manuscript for important intellectual content; all authors contributed to the manuscript and approved the final version to be submitted.
Supported by the Foundation of Science and Technology Bureau of Dalian , No. 2021JJ13SN70 .
Informed consent statement: A written informed consent was obtained from the patient for publication of this case report.
Conflict-of-interest statement: The authors have nothing to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhuo Liu, Doctor, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian 116011, Liaoning Province, China. liuzhuo@firstosp-dmu.com
Received: October 4, 2022
Peer-review started: October 4, 2022
First decision: December 19, 2022
Revised: January 8, 2023
Accepted: January 20, 2023
Article in press: January 20, 2023
Published online: February 16, 2023
Peer-review started: October 4, 2022
First decision: December 19, 2022
Revised: January 8, 2023
Accepted: January 20, 2023
Article in press: January 20, 2023
Published online: February 16, 2023
Core Tip
Core Tip: Combined small cell lung cancer (C-SCLC) is a special subtype of small cell lung cancer, which is relatively rare, aggressive, prone to early metastasis, and has a poor prognosis. With the development and progress of immunotherapy, several clinical studies have shown that programmed death ligand-1 combined with chemotherapy can effectively prolong the progression-free survival and median overall survival of patients with extensive stage small cell lung cancer, but its efficacy in C-SCLC is not exact. In this paper, we report a patient with extensive stage C-SCLC who was treated with envafolimab combined with carboplatin and etoposide with preliminary anti-tumor activity, safety and tolerability.